NR4A1 and breast carcinoma: Baselga and colleagues found that Buparlisib plus fulvestrant significantly improved progression free survival (PFS) by 1.9 months (6.9 vs. 5.0 months, p < 0.001) in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (Baselga et al., 2017).